Active Biotech Delårsrapport januari – september 2019  

   Väsentliga händelser under kvartal 3Framtagande av en ny affärsplan för laquinimod och tasquinimod, baserad på de omfattande tidigare framtagna prekliniska och kliniska data, pågårData från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom presenterades på den internationella kongressen Parkinson’s disease and movement disorders
Händelser efter periodens utgång
Första patienten har doserats i fas 1b-studien av naptumomab estafenatox i kombination med durvalumab i solida tumörerPrekliniska data för naptumomab estafenatox presenterades vid Society for Immunotherapy of Cancer’s 34th Annual MeetingEkonomisk översikt  För ytterligare information, vänligen kontakta:Rapporten finns även tillgänglig på www.activebiotech.com.BilagaActive Biotech Delårsrapport januari – september 2019  

Disclaimer & Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.